Astellas Pharma. has filed a patent for methods of generating and expanding human hemangio-colony forming cells in vitro. These methods allow for the production of large numbers of these cells, which can be used for various research, clinical, and therapeutic applications. GlobalData’s report on Astellas Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Astellas Pharma Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Astellas Pharma, Cancer treatment biomarkers was a key innovation area identified from patents. Astellas Pharma's grant share as of September 2023 was 45%. Grant share is based on the ratio of number of grants to total number of patents.

Methods for generating and expanding human hemangio-colony forming cells